ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for CV Events.
To determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of CV death, MI, stroke or hospitalization for CHF compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.
Randomized, double-blind, parallel group design.
Cardiovascular death Non-fatal myocardial infarction Non-fatal stroke Hospitalization for congestive heart failure. Secondary endpoints: Newly diagnosed CHF. CV revascularization procedures. Newly diagnosed diabetes. Cognitive decline (adjudication done by a special committee). New onset of atrial fibrillation. Nephropathy. All primary and secondary endpoints were adjudicated.